AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05787002
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2
Recruiting
- Conditions
- Hepatocellular CarcinomaBiliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05775159
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Completed
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05775549
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3
Recruiting
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4300
- Registration Number
- NCT05774951
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Phase 3
Active, not recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 142
- Registration Number
- NCT05771480
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05768360
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 373
- Registration Number
- NCT05755906
- Locations
- 🇿🇦
Research Site, Tygervalley, South Africa
Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants
Phase 3
Completed
- Conditions
- Mucociliary Clearance
- Interventions
- Drug: HFO MDIDrug: HFA MDI
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT05755932
- Locations
- 🇬🇧
Research Site, Glasgow, United Kingdom
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05751759
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Phase 3
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Combination Product: PlaceboCombination Product: Tozorakimab 1Combination Product: Tozorakimab 2
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1596
- Registration Number
- NCT05742802
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath